01—Abstract
Summary
Summary of the 8-K filed October 31, 2024. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) furnished a press release dated October 31, 2024 (Exhibit 99.1) reporting third quarter 2024 results for the period ended September 30, 2024.
Total revenue rose 34% year over year to $290.1 milliona, driven by royalty revenue growth and higher milestone revenue. Royalties were $155.1 million, up 36% from $114.4 million, primarily from DARZALEX SC, Phesgo and the prior-year launch of VYVGART Hytrulo. Net income was $137.0 million versus $81.8 million, GAAP diluted EPS was $1.05 versus $0.61, and non-GAAP diluted EPS was $1.27 versus $0.75.
Adjusted EBITDA was $183.6 millionb versus $114.9 million a year earlier. The company raised its 2024 guidance ranges: total revenue of $970 million to $1,020 million (previously $935 million to $1,015 million), royalty revenue of $550 million to $565 million (previously $520 million to $555 million), adjusted EBITDA of $595 million to $625 million (previously $555 million to $615 million), and non-GAAP diluted EPS of $4.00 to $4.20 (previously $3.65 to $4.05). Cash, cash equivalents and marketable securities were $666.3 million at September 30, 2024, compared with $336.0 million at December 31, 2023.
For partner activity, the release notes that argenx expanded its license agreement in September 2024 to four additional targets, for a total of six, with upfront payments of $7.5 millionc per target ($30.0 million total). ViiV added one undisclosed target, and the FDA approved OCREVUS ZUNOVO and TECENTRIQ HYBREZA with ENHANZE in September 2024.
02—Key points
Key Highlights
- Total revenue of $290.1 million, up 34% year over year from $216.0 million
- Royalty revenue of $155.1 million, up 36% from $114.4 million, led by DARZALEX SC and Phesgo
- Net income of $137.0 million versus $81.8 million; GAAP diluted EPS of $1.05 versus $0.61
- Adjusted EBITDA of $183.6 million versus $114.9 million in the prior-year quarter
- 2024 guidance raised: total revenue $970-$1,020 million, adjusted EBITDA $595-$625 million, non-GAAP diluted EPS $4.00-$4.20
- argenx expanded its ENHANZE license to six total targets, with $7.5 million upfront per new target ($30.0 million total) and up to $85.0 million in milestones per new target
- Cash, cash equivalents and marketable securities of $666.3 million at September 30, 2024, up from $336.0 million at December 31, 2023
03—Questions
Frequently Asked Questions
Why did Halozyme's revenue grow in the third quarter of 2024?
The company attributed the 34% year-over-year revenue increase mainly to royalty revenue growth and higher milestone revenue. Royalties rose 36% to $155.1 million, primarily from increased DARZALEX SC and Phesgo revenue and the prior-year launch of VYVGART Hytrulo.
What changed in Halozyme's 2024 financial guidance?
Halozyme raised all four 2024 guidance ranges. Total revenue moved to $970-$1,020 million from $935-$1,015 million, royalty revenue to $550-$565 million from $520-$555 million, adjusted EBITDA to $595-$625 million from $555-$615 million, and non-GAAP diluted EPS to $4.00-$4.20 from $3.65-$4.05. The EPS guidance does not consider potential future share repurchases.
What were the key partner developments in the quarter?
argenx expanded its agreement in September 2024 to four additional targets, for six in total, with $7.5 million upfront per new target. ViiV added one undisclosed target. The FDA approved OCREVUS ZUNOVO and TECENTRIQ HYBREZA with ENHANZE, and TECENTRIQ HYBREZA triggered a $12.0 million milestone payment.
How did Halozyme's profitability and balance sheet change?
Operating income rose to $163.2 million from $88.3 million, and net income rose to $137.0 million from $81.8 million. Cash, cash equivalents and marketable securities reached $666.3 million at September 30, 2024, up from $336.0 million at December 31, 2023, which the company attributed mainly to cash generated from operations. Total stockholders' equity increased to $452.7 million from $83.8 million.
04—Continue